Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats: Role of nitric oxide and angiotensin II type 2 receptors

Hypertension

Volumn 28, Issue 6, 1996, Pages 967-972

  Maeso, Rosaura ^a   Navarro Cid, Josefa ^a   Muñoz García, Raquel ^a   Rodrigo, Elena ^a   Ruilope, Luis Miguel ^b   Lahera, Vicente ^a   Cachofeiro, Victoria ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

angiotensin converting enzyme inhibitors; catecholamines; nitric oxide; receptors, angiotensin II

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLCHOLINE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CYCLIC GMP; LOSARTAN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION;

EID: 0029847665     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.6.967     Document Type: Article

References (29)

1. Zimmerman BG. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci. 1981;60:343-348.
2. Hano T, Mizukoshi M, Baba A, Nakamura N, Nishio I. Angiotensin II subtype I receptor modulates epinephrine release from isolated rat adrenal gland. Blood Pressure. 1994;3(suppl 5):105-108.
3. Khairallah PA. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Fed Proc. 1972;31:1351-1357.
4. Roth RH. Action of angiotensin on adrenergic nerve endings: enhancement of norepinephrine biosynthesis. Fed Proc. 1972;31: 1358-1364.
5. Böke T, Malik KU. Enhancement by locally generated angiotensin II of release of the adrenergic transmitter in the isolated rat kidney. J Pharmacol Exp Ther. 1983;226:900-907.
6. Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res. 1976;38:26-30.
7. Ziogas J, Story DF. Effect of locally generated angiotensin II on noradrenergic neuroeffector function in the rat isolated caudal artery. J Hypertens. 1987;5(suppl 2):S47-S52.
8. Qiu HY, Henrion D, Levy BI. Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Hypertension. 1994; 24:317-321.
9. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
10. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;2:135-165.
11. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992;19:138-145.
12. 2 receptors, prostaglandins, kinins and nitric oxide. J Hypertens. 1995;13:1779-1784.
13. Brooker G, Harper JF, Terasaki WL, Moylan RD. Radioimmunoassay of cyclic AMP and cyclic GMP. In: Brooker G, Greengard P, Robison GA, eds. Advances in Cyclic Nucleotide Research. New York, NY: Raven Press Publishers; 1979;10:1-33.
14. ω-nitro-L-arginine. Hypertension. 1991;18:683-688.
15. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediated nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
16. Oparil S, Chen YF, Berecek KH, Calhoun DA, Wyss JM. The role of the central nervous system in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press Publishers; 1995:713-740.
17. Esler M. The sympathetic nervous system and catecholamine release and plasma clearance in normal blood pressure control, in aging, and in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press Publishers; 1995:755-773.
18. Israel A, Strömberg C, Tsutsumi K, Garrido MR, Torres M, Saavedra JM. Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Brain Res Bull. 1995;38:441-446.
19. Poggioli J, Lazar G, Houillier P, Gardin JP, Achard JM, Paillard M. Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule. Am J Physiol. 1992; 263:C750-C758.
20. Ko Y, Görg A, Appenheimer M, Wieczorek AJ, Dusing R, Vetter H, Sachinidis A. Losartan inhibits the angiotensin II induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells. Eur J Pharmacol. 1992;277:215-219.
21. Burnier MG, Centeno E, Grozmann P, Walker B, Waemer B, Brinner H. In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist on human platelets and rat vascular smooth muscle cells. Am J Hypertens. 1991;4:438-443.
22. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM. In vitro pharmacology of DuP 753. Am J Hypertens. 1991;4:282S-287S.
23. Cachofeiro V, Guan H, Miller K, Nasjletti A. The antihypertensive effect of losartan as affected by vascular cyclic GMP in SHR. J Hypertens. 1994;12:588. Abstract.
24. Guan H, Cachofeiro V, Pucci ML, Kaminski PM, Wolin MS, Nasjletti A. Nitric oxide and the depressor response to angiotensin blockade in hypertension. Hypertension. 1996;27:19-24.
25. 2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett. 1993;3:24-27.
26. Atkinson J, Sonnay M, Sautel M, Fouda A-K. Chronic treatment of spontaneously hypertensive rat with captopril attenuates responses to noradrenaline in vivo but not in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1987;335:624-628.
27. Antonaccio MJ, Kervin L. Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol. 1980;68:209-212.
28. Rubin B, Laffan RJ, Kotler DG, O'Keefe E, Demaio DA, Goldberg ME. SQ 14,225 (D-3 mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther. 1978;204:271-290.
29. Husain A. The chymase-angiotensin system in humans. J Hypertens. 1993;11:1155-1159.